Merrill keeps Amgen at neutral

Amgen Inc. was maintained at a neutral rating by Merrill Lynch analyst Eric Ende after Aranesp received a Food and Drug Administration approvable letter for bi-weekly and once-monthly dosing in chronic kidney disease patients with anemia not undergoing dialysis. Expanded approval could be delayed by 12 to 18 months after the FDA requested an additional clinical trial, according to Ende. The delay could increase the potential for competitive risks from Roche's once-monthly Cera, however, infringement issues may prevent a U.S. launch. Shares of the Thousand Oaks, Calif.-based biotechnology company were down 79 cents, or 1.08%, at $72.43. (Nasdaq: AMGN)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.